Navigation Links
Cornerstone Therapeutics Announces Closing of Chiesi Transaction
Date:7/30/2009

Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning at 11:30 AM ET on August 11th at 888-286-8010 (U.S. callers) or 617-801-6888 (international callers), passcode 84986553.

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (Nasdaq: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with a recent regulatory submission filing and four additional regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force which is focused on the respiratory and related markets; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Safe Harbor Statement

Statements in this press release regarding the progress and timing of our product devel
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
2. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
3. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
4. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
5. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
6. Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date
7. PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
8. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
9. United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
10. Cell Therapeutics, Inc. Announces Exercise of Overallotment
11. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The report “Service Quality Management and Telco Customer Experience ... Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines and ... of revenues. , Browse 152 market data tables, ... on “Service Quality Management (SQM) and Telco Customer Experience ...
(Date:12/24/2014)... 2014  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical ... that the Company closed its previously announced private ... Jack W. Schuler , Birchview Fund LLC and ... before offering expenses.  The proceeds will be used ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... Swiss biotechnology company, Syngenta, are in the process of being ... consolidated case is In Re: Syngenta AG MIR 162 Corn ... the District of Kansas. , Management of the Syngenta GMO ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... Continuing Resolution Appropriations Act of 2015, which for the ... funding through the Congressionally Directed Medical Research Programs (CDMRP) ... Association (HA), working in conjunction with its allies on ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... HONG KONG, Oct. 1 /PRNewswire-Asia/ -- Golden Meditech Company ... a leading hi-tech medical device and healthcare service corporation ... Golden Meditech Hospital Group (GMHG) has entered into an ... in 2014 with an aggregate principal amount of US$28 ...
... ... Academia to Come Together for Virtual Conference and Networking at www.BioConferenceLive.com , ... Boston, MA (PRWEB) -- PlatformQ ... LabRoots , a free social networking site serving the scientific community, today announced that ...
... DOR BioPharma, Inc. (OTC Bulletin Board: SNGX), a late-stage biotechnology ... change from DOR BioPharma, Inc. to Soligenix, Inc. (Soligenix or ... Company,s shares of common stock will immediately begin trading under ... , "We are pleased to announce the name change of ...
Cached Biology Technology:Golden Meditech Announces HK$217 Million Private Equity Financing for Hospital Subsidiary 2CEO of Burrill & Company to Speak at BioConference Live Slated for November 17th and 18th 2CEO of Burrill & Company to Speak at BioConference Live Slated for November 17th and 18th 3DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 2DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 3DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 4
(Date:12/22/2014)... (NASDAQ: NXTD and NXTDW) ("NXT-ID" or the ... commerce market, announces it has retained famous pickpocket, entertainer and ... CES debut of the Wocket™ biometric smart wallet.  ... booth January 6th and 7 th , 2015, demonstrating some ...
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has ... Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of ... feature with the iPhone 5S. It is currently the ...
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... have long known that people who have a close relative ... to abuse alcohol. The reason for this has not been ... Sweden, provides part of the answer. The study shows that ... react more positively to alcohol than other people. , The ...
... Laboratory studies by chemical engineers at UC Santa ... detection and diagnosis and to possible treatments ... and similar diseases. Achieving a new method of ... the membrane surrounding nerves that is compromised in patients ...
... Administration requires every drug they certify to be tested ... gold standard for this is the limulus amoebocyte lysate ... crabs, which strangely enough is blue, to test for ... by bacterial infections. But researchers at the Department ...
Cached Biology News:Heredity behind subjective effects of alcohol 2New nanoscale imaging may lead to new treatments for multiple sclerosis 2Replacing the blue bloods 2
Potassium Channel kv3.2...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
MAb to Vasopressin Preservative: NaN3...
Biology Products: